Loading...

PE anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Pricing & Availability
Clone
RB6-8C5 (See other available formats)
Regulatory Status
RUO
Other Names
Gr-1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
RB6-8C5_PE_040912
C57BL/6 mouse bone marrow cells were stained with Ly-6G/Ly-6C (clone RB6-8C5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram). Data shown was gated on myeloid cell population.
  • RB6-8C5_PE_040912
    C57BL/6 mouse bone marrow cells were stained with Ly-6G/Ly-6C (clone RB6-8C5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram). Data shown was gated on myeloid cell population.
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
108407 50 µg 45€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108408 200 µg 147€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Ostapoff K, et al. 2014. Cancer Res. 74:4966. PubMed
  2. Drobek A, et al. 2015. J Immunol. 195: 3416 - 3426. PubMed
  3. Chinta KC et al. 2018. Cell reports. 25(7):1938-1952 . PubMed
  4. Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed
  5. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  6. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  7. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  8. Xiong T, et al. 2022. Cancer Sci. 113:1955. PubMed
  9. Roberts LM, et al. 2022. Cancers (Basel). 14: . PubMed
  10. Albayrak E, et al. 2022. J Cell Biochem. 123:2009. PubMed
  11. Shang T, et al. 2022. Front Pharmacol. 13:1054176. PubMed
  12. Kodali S, et al. 2022. J Immunol. 208:1085. PubMed
  13. Ramdas B, et al. 2022. Mol Ther. 30:2505. PubMed
  14. Pomatto-Watson LCD, et al. 2022. Geroscience. 44:2471. PubMed
  15. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  16. Brunner SM, et al. 2023. Int J Mol Sci. 24:. PubMed
  17. Dang YZ, et al. 2023. Neoplasma. 70:123. PubMed
  18. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  19. Ji Y, et al. 2023. Nat Cell Biol. 25:726. PubMed
  20. Jackson A, et al. 2014. J Leukoc Biol. 92:609. PubMed
  21. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  22. Baryawno N et al. 2019. Cell. 177(7):1915-1932 . PubMed
  23. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  24. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  25. Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed
  26. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  27. Riether C, et al. 2021. Cell Reports. 34(4):108663. PubMed
  28. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  29. Voronov E, et al. 2010. Int Immunol. 1.086805556. PubMed
  30. Matsushita Y, et al. 2021. J Bone Miner Res. 36:1145. PubMed
  31. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  32. Hu J, et al. 2021. Sci Adv. 7:. PubMed
  33. Shen H, et al. 2015. Infect Immun . 83: 2694 - 2704. PubMed
  34. Feng M, et al. 2014. Int Immunopharmacol. 19:267. PubMed
  35. Liu X, et al. 2013. Diabetes. 62:4228. PubMed
  36. Lee Y, et al. 2017. PLoS One.. 10.1371/journal.pone.0183028. PubMed
  37. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  38. Martin R, et al. 2014. J Leukoc Biol. 96:151. PubMed
  39. Ohtsuki T, et al. 2016. J Virol. 90: 300 - 307. PubMed
  40. Peng J, et al. 2016. Nat Commun. 7:12029. PubMed
  41. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  42. Brunner JS, et al. 2020. Nat Commun. 0.757638889. PubMed
  43. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  44. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  45. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  46. Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
  47. Liu YY, et al. 2020. Chin Med J (Engl). 133:1688. PubMed
  48. Crnej A, et al. 2015. Invest Ophthalmol Vis Sci . 56:185. PubMed
  49. Etxeberria I, et al. 2020. Cancer Cell. 36(6):613-629. PubMed
  50. Dey A et al. 2019. The EMBO journal. 38(7) pii: e100293. PubMed
  51. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  52. Kan C, et al. 2022. Bone Res. 10:62. PubMed
  53. Balachandran Y, et al. 2022. J Innate Immun. :1. PubMed
  54. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  55. Gordon RA, et al. 2020. PLoS One. 15:e0226396. PubMed
  56. Hawila E, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.104. PubMed
  57. Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed
  58. Li J, et al. 2019. JCI Insight. 5. PubMed
  59. Casey S, et al. 2011. Mol Endocrinol. 25:933. PubMed
  60. Keshavarz M, et al. 2020. Virol J. 17:64. PubMed
  61. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  62. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  63. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  64. Nayak RR, et al. 2021. Cell Host Microbe. 29(3):362-377.e11. PubMed
  65. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  66. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  67. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
  68. Curtis MW, et al. 2018. Infect Immun. 86:e00186. PubMed
  69. Grzelak A, et al. 2018. Int J Mol Sci. 19:. PubMed
  70. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  71. Stumpfova M, et al. 2010. Cancer Res . 70:2962. PubMed
  72. Dang Y, et al. 2021. J Cancer. 12:7158. PubMed
  73. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  74. Yoon Y, et al. 2016. Stem Cell Reports. 7:840-853. PubMed
  75. Lira R, et al. 2016. PLoS One. 11: 0157475. PubMed
  76. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  77. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  78. Suresh MV, et al. 2019. JCI Insight. 4:e133103. PubMed
  79. Yang M, et al. 2021. Cancer Immunol Immunother. 70:2467. PubMed
  80. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  81. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  82. Xiang W, et al. 2018. Nat Commun. 9:2574. PubMed
  83. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  84. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  85. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  86. Yan W, et al. 2021. Front Med (Lausanne). 8:752223. PubMed
  87. Aktories P, et al. 2022. Cell Rep Methods. 2:100260. PubMed
  88. Pashover-Schallinger E, et al. 2012. FASEB J. 26:3891. PubMed
  89. Wang Q, et al. 2018. Int J Biol Sci. 14:147. PubMed
  90. Uslu M, et al. 2020. J Cell Physiol. 235:9644. PubMed
  91. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  92. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  93. Patankar Y, et al. 2015. Am J Physiol Lung Cell Mol Physiol. 309: L902 - L913. PubMed
  94. Merlo LM, et al. 2020. Clin Pathol. 13:2632010X20951812. PubMed
  95. Akk A, et al. 2019. Mol Immunol. 114:629. PubMed
  96. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  97. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  98. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  99. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  100. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  101. Chen Y, et al. 2022. Life Sci. 306:120826. PubMed
  102. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  103. Ostapoff K, et al. 2013. Mol Cancer Ther. 12:1190. PubMed
  104. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  105. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  106. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  107. Rashid O, et al. 2013. Surgery. 153:771. PubMed
  108. Mosa A, et al. 2009. Infect Immun. 77:2908. PubMed
  109. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  110. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  111. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  112. Koide S, et al. 2022. iScience. 25:103603. PubMed
  113. Filina J, et al. 2014. Cell Signal. 26:2138. PubMed
  114. Weckbach LT, et al. 2019. J Exp Med. 216:350. PubMed
  115. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  116. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  117. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  118. Iwanami N, et al. 2020. iScience. 23:101260. PubMed
  119. Beyerle A, et al. 2011. J Control Release. 151:51. PubMed
  120. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  121. Hsia HC, et al. 2017. J Leukoc Biol. 101:1053. PubMed
  122. Jordan PM, et al. 2021. Pharmaceuticals (Basel). 14:. PubMed
  123. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
  124. Darlyuk-Saadon I, et al. 2021. FEBS J. 288:3978. PubMed
  125. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  126. Chen J, et al. 2021. Oncol Lett. 21:409. PubMed
  127. Hegde V, et al. 2015. J Immunol. 194:5211. PubMed
  128. Rowe R, et al. 2016. J Exp Med. 213: 1497 - 1512. PubMed
  129. Evavold CL, et al. 2021. Cell. 184(17):4495-4511.e19. PubMed
  130. Ioanna E Galani et al. 2017. Immunity. 46(5):875-890 . PubMed
  131. Zhang M, et al. 2019. Autophagy. 1.423611111. PubMed
  132. Franklin R, et al. 2022. Nat Commun. 13:2350. PubMed
  133. Xie Y, et al. 2020. Endocrinology. 161:00:00. PubMed
  134. Ramos-Sevillano E, et al. 2016. PLoS One. 12: 1005500. PubMed
  135. Weimershaus M, et al. 2012. J Immunol. 188:1789. PubMed
  136. Guarnerio J, et al. 2018. Nat Commun. 9:66. PubMed
  137. Moriyasu T, et al. 2018. PLoS Negl Trop Dis. 12:e0006197. PubMed
  138. Terlizzi M, et al. 2021. Cell Physiol Biochem. 55:539. PubMed
RRID
AB_313372 (BioLegend Cat. No. 108407)
AB_313373 (BioLegend Cat. No. 108408)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All Ly-6G/Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
FITC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC
Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,SB
Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IP,CMCD,Depletion,IHC,WB
Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 IHC-F,FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready) RB6-8C5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody RB6-8C5 FC
Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1) RB6-8C5 FC
Spark Violet™ 538 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Go To Top Version: 2    Revision Date: 12.09.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account